Source - SMW
ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline announced Thursday that it filed a patent infringement litigation against Gilead Sciences over bictegravir in the United States and Canada.

'ViiV Healthcare will seek to prove that Gilead Sciences Inc's triple combination HIV drug containing the HIV integrase inhibitor bictegravir infringes ViiV Healthcare's patent covering ViiV Healthcare's dolutegravir and many other compounds that include dolutegravir's unique chemical scaffold,' the company said in statement.